Brazilian regulators have given their approval for the start of human clinical trials on ButanVac, a coronavirus vaccine developed by São Paulo’s Butantan Biological Institute.
The São Paulo government says production will be entirely domestic, though the immunizer uses technology developed by the Icahn School of Medicine at the New York-based Mount Sinai Health System.
Butantan has been waiting for approval since April and claims to have already produced 7 million doses of the vaccine, despite being a long way away from obtaining emergency use clearance. According to Butantan head Dimas Covas, the Health Ministry showed an interest in purchasing 30 million doses of ButanVac.
Search
